Teclistamab-associated cytokine release syndrome in multiple myeloma: a case-based literature review of mechanisms, management, and clinical implications

医学 托珠单抗 细胞因子释放综合征 美罗华 细胞激素风暴 机械通风 免疫学 重症监护医学 内科学 免疫系统 免疫疗法 淋巴瘤 嵌合抗原受体 疾病 类风湿性关节炎 传染病(医学专业) 2019年冠状病毒病(COVID-19)
作者
Muhammad Arslan Cheema,Salman Syed,ZOHA GHUMAN,Asma Iftikhar
出处
期刊:Archive of Clinical Cases [Grigore T. Popa University of Medicine and Pharmacy]
卷期号:12 (2): 98-101 被引量:3
标识
DOI:10.22551/2025.47.1202.10320
摘要

Cytokine release syndrome (CRS) is a potentially life-threatening inflammatory condition that can occur after immune-based therapies, such as bispecific antibodies. We present the case of a 66-year-old woman with relapsed/refractory multiple myeloma who developed fatal CRS following treatment with Teclistamab, a bispecific antibody that targets CD3 on T cells and B-cell maturation antigen on myeloma cells. The patient had previously achieved remission with rituximab, bortezomib, and autologous stem cell transplantation but experienced a relapse after eight years. Teclistamab was initiated with a step-up dosing regimen. Before treatment, she received premedication with intravenous fluids, steroids, and tocilizumab. Despite this premedication, the patient was readmitted with fever, chills, and shortness of breath, leukopenia, and hypoxia. Imaging studies indicated pneumonia. During her hospitalization, her condition deteriorated rapidly, resulting in respiratory failure and refractory shock. She was transferred to the intensive care unit (ICU), where she required mechanical ventilation and multiple pressor support. Despite aggressive resuscitation efforts, she progressed to multi-organ failure, and the family ultimately chose to withdraw care. CRS is characterized by a systemic inflammatory response with rapid and excessive release of cytokines, particularly IL-6, IL-2, IL-10, IFN-γ, and GM-CSF. Severe CRS can clinically resemble sepsis. Management strategies include early recognition, supportive care, and immunomodulatory therapy, particularly with tocilizumab and corticosteroids. This case underscores the diagnostic and therapeutic challenges of differentiating severe CRS from infection. This case uniquely contributes to current understanding by highlighting the limitations of current premedication protocols and emphasizing the critical need for enhanced monitoring and rapid intervention protocols in managing Teclistamab-induced CRS. It highlights the critical need for prompt, targeted intervention to prevent fatal outcomes in patients receiving novel immunotherapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
vvkaway完成签到,获得积分10
刚刚
哈哈哈发布了新的文献求助10
刚刚
久某完成签到,获得积分10
刚刚
mary发布了新的文献求助10
刚刚
1秒前
挚友发布了新的文献求助10
1秒前
SciGPT的应助被dgb采纳,获得10
1秒前
quw88888发布了新的文献求助10
1秒前
1秒前
ganyanhui发布了新的文献求助10
2秒前
完美世界的应助被友好元槐采纳,获得10
2秒前
汉堡包的应助被可可采纳,获得10
2秒前
2秒前
小二郎的应助被卓尔不群金良采纳,获得10
3秒前
3秒前
充电宝的应助被chiyudawang采纳,获得10
3秒前
虚幻雪一发布了新的文献求助10
3秒前
桐桐的应助被lalala采纳,获得10
4秒前
蓝意发布了新的文献求助10
4秒前
4秒前
molihuakai的应助被彪壮的绮烟采纳,获得10
5秒前
Maestro_S的应助被张若虚采纳,获得10
5秒前
5秒前
落后夏之发布了新的文献求助10
6秒前
molihuakai的应助被嘟噜采纳,获得10
6秒前
6秒前
Cc发布了新的文献求助10
6秒前
LL完成签到,获得积分10
7秒前
7秒前
Akim的应助被ZND采纳,获得10
7秒前
洋芋大大王完成签到 ,获得积分10
7秒前
Hao发布了新的文献求助10
7秒前
8秒前
ganyanhui完成签到,获得积分10
8秒前
8秒前
8秒前
wanci的应助被单薄翠绿采纳,获得10
9秒前
9秒前
热心的荣轩完成签到,获得积分10
10秒前
Akim的应助被Xia采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178203
求助须知:如何正确求助?哪些是违规求助? 9568998
关于积分的说明 21802098
捐赠科研通 7773088
什么是DOI,文献DOI怎么找? 3432711
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478259